What does this research mean for the field?

Lower therapeutic ranges for anticoagulation do not significantly increase thromboembolic risk in most patients with mechanical heart valves, but may be associated with higher risk in patients with non-aortic valves and additional risk factors. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

The research aims to assess how different therapeutic INR ranges impact anticoagulation control and clinical outcomes in patients with mechanical heart valves treated with VKAs.

January 8, 2026Thrombosis and HaemostasisOpen Access

Anticoagulation therapeutic ranges and clinical outcomes in patients with a mechanical heart valve treated with vitamin K antagonists

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: mechanical heart valve replacement (n=3473). Intervention: Vitamin K antagonists (VKAs). Primary outcome: Thromboembolic risk in patients with non-aortic valve and/or additional risk factors (aHR 1.3, 95% CI 0.94-1.9).

View Full Paper

Ask AI

Bookmark

Key result

A lower therapeutic range does not significantly increase thromboembolic risk in most patients with mechanical heart valves but may be associated with a higher risk in patients with non-aortic valves and additional risk factors.

Authors

CVChantal A.N. Visser EKEva K Kempers JSJaap Seelig

Discussion

Member takes

Overview

A study examines anticoagulation effects on outcomes in mechanical heart valve patients, suggesting differing risks based on therapeutic ranges.

Key Points

The research aims to assess how different therapeutic INR ranges impact anticoagulation control and clinical outcomes in patients with mechanical heart valves treated with VKAs.
Linked data from 17 anticoagulation clinics and national statistics from 2013-2019.
Analyzed anticoagulation control metrics including INR variance growth rate and time in therapeutic range.
Used cause-specific Cox regression models to evaluate associations between therapeutic ranges and clinical outcomes.
Lower therapeutic ranges resulted in poorer anticoagulation control among patients compared to higher ranges.
No significant association between therapeutic ranges and major bleeding was found.
In higher risk patients, a lower therapeutic range was potentially linked to increased thromboembolic risk.

Study Design

Type

Cohort (n=3,473)

Multicenter

Yes

PICO

Population

mechanical heart valve replacement (n=3,473)

Intervention / Comparator

Vitamin K antagonists (VKAs)

Primary Outcome

Thromboembolic risk in patients with non-aortic valve and/or additional risk factors — aHR 1.3 (0.94-1.9)

Main Result

Effect estimate: aHR 1.3 (95% CI 0.94-1.9)

Limitations

Single-center study
Data limited to Netherlands
No specific details on INR control metrics

Cite This Study

Visser et al. (2026) conducted a cohort in mechanical heart valve replacement (n=3,473). Vitamin K antagonists (VKAs) was evaluated on Thromboembolic risk in patients with non-aortic valve and/or additional risk factors (aHR 1.3, 95% CI 0.94-1.9). A lower therapeutic range does not significantly increase thromboembolic risk in most patients with mechanical heart valves but may be associated with a higher risk in patients with non-aortic valves and additional risk factors.

synapsesocial.com/papers/69608779fa51ca23bb9809a3 https://doi.org/10.1055/a-2773-5810

View Full Paper

Ask AI

Bookmark

January 8, 2026Thrombosis and HaemostasisOpen Access

Anticoagulation therapeutic ranges and clinical outcomes in patients with a mechanical heart valve treated with vitamin K antagonists

View Full Paper

Ask AI

Bookmark

Key result

Authors

CVChantal A.N. Visser EKEva K Kempers JSJaap Seelig

Discussion

Member takes

Overview

A study examines anticoagulation effects on outcomes in mechanical heart valve patients, suggesting differing risks based on therapeutic ranges.

Key Points

The research aims to assess how different therapeutic INR ranges impact anticoagulation control and clinical outcomes in patients with mechanical heart valves treated with VKAs.
Linked data from 17 anticoagulation clinics and national statistics from 2013-2019.
Analyzed anticoagulation control metrics including INR variance growth rate and time in therapeutic range.
Used cause-specific Cox regression models to evaluate associations between therapeutic ranges and clinical outcomes.
Lower therapeutic ranges resulted in poorer anticoagulation control among patients compared to higher ranges.
No significant association between therapeutic ranges and major bleeding was found.
In higher risk patients, a lower therapeutic range was potentially linked to increased thromboembolic risk.

Study Design

Type

Cohort (n=3,473)

Multicenter

Yes

PICO

Population

mechanical heart valve replacement (n=3,473)

Intervention / Comparator

Vitamin K antagonists (VKAs)

Primary Outcome

Thromboembolic risk in patients with non-aortic valve and/or additional risk factors — aHR 1.3 (0.94-1.9)

Main Result

Effect estimate: aHR 1.3 (95% CI 0.94-1.9)

Limitations

Single-center study
Data limited to Netherlands
No specific details on INR control metrics

Cite This Study

synapsesocial.com/papers/69608779fa51ca23bb9809a3 https://doi.org/10.1055/a-2773-5810

View Full Paper

Ask AI

Bookmark